Cargando…

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

The gene and cell therapy field saw its first approved treatments in Europe in 2012 and the United States in 2017 and is projected to be at least a $10B USD industry by 2025. Despite this success, a massive gap exists between the companies, clinics, and researchers developing these therapeutic appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adair, Jennifer E., Androski, Lindsay, Bayigga, Lois, Bazira, Deus, Brandon, Eugene, Dee, Lynda, Deeks, Steven, Draz, Mohamed, Dubé, Karine, Dybul, Mark, Gurkan, Umut, Harlow, Evelyn, Kityo, Cissy, Louella, Michael, Malik, Punam, Mathews, Vikram, McKemey, Adrian, Mugerwa, Henry, Muyanja, Daniel, Olayiwola, Olabimpe, Orentas, Rimas J., Popovski, Alex, Sheehy, Jeff, Ssali, Francis, Nsubuga, Moses Supercharger, Tisdale, John F., Verhoeyen, Els, Dropulić, Boro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113145/ https://www.ncbi.nlm.nih.gov/pubmed/34493840 http://dx.doi.org/10.1038/s41434-021-00284-4

Ejemplares similares

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
por: Han, Bin, et al.
Publicado: (2012)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
por: Schneider, Dina, et al.
Publicado: (2017)

Melanoma Cells Treated with GGTI and IFN-γ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells
por: Sarrabayrouse, Guillaume, et al.
Publicado: (2010)

Chimeric engulfment receptors: A new cell therapy approach for SIV and HIV infection
por: Orentas, Rimas J.
Publicado: (2023)

Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells
por: Paugh, Barbara S., et al.
Publicado: (2021)

Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells
por: Baranyi, Lajos, et al.
Publicado: (2012)

A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda
por: Reynolds, Steven J., et al.
Publicado: (2010)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma
por: Long, Adrienne H, et al.
Publicado: (2013)

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

The ALEPH calorimeter response to pion showers
por: Green, M, et al.
Publicado: (1988)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

Towards a commercial process for the manufacture of genetically modified T cells for therapy
por: Kaiser, A D, et al.
Publicado: (2015)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
por: Highfill, Steven L, et al.
Publicado: (2013)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States
por: Dubé, Karine, et al.
Publicado: (2022)

In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
por: Anthony-Gonda, Kim, et al.
Publicado: (2022)

Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
por: Orentas, Rimas J., et al.
Publicado: (2012)

Dispersal of Engineered Male Aedes aegypti Mosquitoes
por: Winskill, Peter, et al.
Publicado: (2015)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison
por: Orentas, Rimas J., et al.
Publicado: (2014)

Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services—A Qualitative Study in 19 Ugandan Districts
por: Bajunirwe, Francis, et al.
Publicado: (2018)

Stable Transcriptional Repression and Parasitism of HIV-1
por: Shrivastava, Surya, et al.
Publicado: (2018)

Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen
por: Zheng, Jin, et al.
Publicado: (2007)

Paired Expression Analysis of Tumor Cell Surface Antigens
por: Orentas, Rimas J., et al.
Publicado: (2017)

Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda
por: Bajunirwe, Francis, et al.
Publicado: (2016)

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
por: Maschan, Michael, et al.
Publicado: (2021)

Genetic control of Aedes aegypti: data-driven modelling to assess the effect of releasing different life stages and the potential for long-term suppression
por: Winskill, Peter, et al.
Publicado: (2014)

Suppression of a Field Population of Aedes aegypti in Brazil by Sustained Release of Transgenic Male Mosquitoes
por: Carvalho, Danilo O., et al.
Publicado: (2015)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
por: Musana, Hellen, et al.
Publicado: (2021)

Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans
por: Nanzigu, Sarah, et al.
Publicado: (2013)

Correction: Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study
por: Inzaule, Seth C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l44bn1lpvh1hkhcbc99ta6616v